Published in Cancer Res on January 01, 1995
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer (2004) 1.79
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol (2004) 1.57
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol (1998) 1.41
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
EPMA position paper in cancer: current overview and future perspectives. EPMA J (2015) 1.04
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer (2006) 1.03
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer (1999) 1.01
Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat Commun (2016) 0.98
N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer (2002) 0.97
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett (2013) 0.93
Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resection. J Transl Med (2013) 0.92
Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg (1997) 0.90
Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest (2010) 0.89
The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg (1995) 0.89
High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC). J Clin Pathol (2006) 0.89
Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J Clin Pathol (2003) 0.86
Protein signature for non-small cell lung cancer prognosis. Am J Cancer Res (2014) 0.85
Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J Korean Med Sci (2006) 0.84
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol (2010) 0.84
Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC Cancer (2015) 0.83
G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer. BMC Cancer (2004) 0.82
New prognostic factors in resectable non-small cell lung cancer. Thorax (1996) 0.81
Serum p53 antibodies: predictors of survival in small-cell lung cancer? Br J Cancer (2000) 0.78
Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue. Br J Cancer (1997) 0.77
Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. Lung Cancer (2013) 0.77
Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer. Thorax (1998) 0.76
Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One (2011) 0.76
Pre-existing Pulmonary Diseases and Survival in Patients With Stage-dependent Lung Adenocarcinoma: A STROBE-compliant Article. Medicine (Baltimore) (2016) 0.75
Detection of HER2 polymorphism and expression using circulating DNA and RNA as a tool in lung adenocarcinoma patients: a case control study. Ann Transl Med (2016) 0.75
Factors affecting 30-month survival in lung cancer patients. Indian J Med Res (2012) 0.75
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.75
Rib metastasis appearing 8 years after surgery for lung cancer: report of a case. Surg Today (2000) 0.75
Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A (2001) 13.30
BRCA2 mutations in primary breast and ovarian cancers. Nat Genet (1996) 2.91
High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A (2000) 2.70
Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest (2000) 2.69
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene (2008) 2.47
Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A (1991) 2.27
A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res (2001) 2.22
Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res (1991) 2.20
Identification of a new virulence locus in Agrobacterium tumefaciens that affects polysaccharide composition and plant cell attachment. J Bacteriol (1987) 2.08
Staging non-small cell lung cancer with whole-body PET. Radiology (1999) 2.07
Molecular cloning and restriction endonuclease mapping of the murine cytomegalovirus genome (Smith Strain). Virology (1983) 2.06
Comparison of omental and pectoralis flaps for poststernotomy mediastinitis. Ann Thorac Surg (1999) 2.05
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol (1991) 2.05
Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol (1999) 1.95
Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res (1992) 1.93
Artificial neural networks improve the accuracy of cancer survival prediction. Cancer (1997) 1.91
HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.89
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A (1992) 1.87
Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. J Biol Chem (1995) 1.78
Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol (1994) 1.77
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Aneurysm of aberrant subclavian artery with a review of the literature. J Vasc Surg (1985) 1.60
p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol (1996) 1.59
Maintenance of p53 alterations throughout breast cancer progression. Cancer Res (1991) 1.58
Alterations of the TP53 gene in human gliomas. Cancer Res (1994) 1.58
Pulmonary abnormalities and PET data analysis: a retrospective study. Radiology (1997) 1.56
Nonpalpable breast lesions at biopsy. A detailed analysis of radiographic features. Ann Surg (1988) 1.55
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer (2009) 1.49
Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. Am J Cardiol (1991) 1.48
BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ (1996) 1.45
Resection of abdominal aortic aneurysm in patients with low ejection fractions. J Vasc Surg (1989) 1.44
Use of paravertebral block anesthesia in the surgical management of breast cancer: experience in 156 cases. Ann Surg (1998) 1.43
Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg (1992) 1.43
Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ (1994) 1.42
A pathological study of unsuccessful cardiac resuscitation. Arch Surg (1968) 1.42
Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer (2001) 1.41
Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg (1995) 1.40
Effects of standard mitral valve replacement on left ventricular function. Ann Thorac Surg (1990) 1.40
Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst (1994) 1.39
Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res (1998) 1.36
Cell cycle control of BRCA2. Cancer Res (1996) 1.32
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol (1998) 1.32
Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol (2000) 1.31
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg (1995) 1.31
M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene (1996) 1.31
Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery (1991) 1.31
Transcription in mouse embryo cells permissively infected by murine cytomegalovirus. Virology (1983) 1.30
Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (1992) 1.28
Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer (1995) 1.27
Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg (1993) 1.27
Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog (1996) 1.27
Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br J Cancer (1998) 1.25
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer (2006) 1.25
Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol (1998) 1.24
BRCA1 expression is not directly responsive to estrogen. Oncogene (1997) 1.24
Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer (2006) 1.23
Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol (1998) 1.21
Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene (1989) 1.20
Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. J Thorac Cardiovasc Surg (1999) 1.20
Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys (1999) 1.19
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2000) 1.19
Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer (1999) 1.18
Comparison of plain radiography, conventional tomography, and computed tomography in detecting intrathoracic lymph node metastases from lung carcinoma. Radiology (1982) 1.16
The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol (1994) 1.16
Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol (1993) 1.16
Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res (1990) 1.15
High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol (1997) 1.14
Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst (1992) 1.13
Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene (1992) 1.13
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ (2000) 1.13
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology (1991) 1.13
Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg (1997) 1.12
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol (1998) 1.12
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol (1993) 1.12
Dhh1 regulates the G1/S-checkpoint following DNA damage or BRCA1 expression in yeast. J Surg Res (2003) 1.12
p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem (1992) 1.12
Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol (1992) 1.11
Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res (1992) 1.11
Experimental and clinical experience with hyperbaric oxygen in the treatment of clostridial myonecrosis. Surgery (1975) 1.10
Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol (2005) 1.10
A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg (1999) 1.10
Subvalvular left ventricular pseudoaneurysm after mitral valve replacement: two-dimensional echocardiographic findings. J Am Coll Cardiol (1985) 1.10